Evidence map›Paper›PMID 24817885›Full record

ArticleInternational journal of endocrinology2014

Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation.

Brian P Boerner, Clifford D Miles, Vijay Shivaswamy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. International consensus on post-transplantation diabetes mellitus.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Post-Transplantation Diabetes Mellitus.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
    Review
  11. Review
  12. Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Brian P BoernerDepartment of Internal Medicine, University of Nebraska Medical Center, 984130 Nebraska Medical Center, Omaha, NE 68198, USA.
Clifford D MilesDepartment of Internal Medicine, University of Nebraska Medical Center, 984130 Nebraska Medical Center, Omaha, NE 68198, USA.
Vijay ShivaswamyDepartment of Internal Medicine, University of Nebraska Medical Center, 984130 Nebraska Medical Center, Omaha, NE 68198, USA ; VA Nebraska-Western Iowa Health Care System, University of Nebraska Medical Center, 4101 Woolworth Avenue, Omaha, NE 68105, USA.ORCID 0000-0002-3301-4965
University of Nebraska Medical Center · USVA Nebraska Western Iowa Health Care System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New-onset diabetes after transplantation (NODAT) is a common comorbidity after renal transplantation. Though metformin is the first-line agent for the treatment of type 2 diabetes, in renal transplant recipients, metformin is frequently avoided due to concerns about renal dysfunction and risk for lactic acidosis. Therefore, alternative first-line agents for the treatment of NODAT in renal transplant recipients are needed. Sitagliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor, has a low incidence of hypoglycemia, is weight neutral, and, in a small study, did not affect immunosuppressant levels. However, long-term sitagliptin use for the treatment of NODAT in kidney transplant recipients has not been studied. We retrospectively analyzed renal transplant recipients diagnosed with NODAT and treated with sitagliptin to assess safety and efficacy. Twenty-two patients were started on sitagliptin alone. After 12 months of followup, 19/22 patients remained on sitagliptin alone with a significant improvement in hemoglobin A1c. Renal function and immunosuppressant levels remained stable. Analysis of long-term followup (32.5 ± 17.8 months) revealed that 17/22 patients remained on sitagliptin (mean hemoglobin A1c < 7%) with 9/17 patients remaining on sitagliptin alone. Transplant-specific adverse events were rare. Sitagliptin appears safe and efficacious for the treatment of NODAT in kidney transplant recipients.

Identifiers

PMID24817885
PMCPMC4003765
OpenAlexW2066723711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.